Compare Stocks: PLRX, RNAC, MGNX, and QTTB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MGNX MacroGenics	$3.92 -3.9%	$4.23	$1.29 ▼ $5.08	$259.34M	1.2	724,178 shs	477,328 shs
PLRX Pliant Therapeutics	$1.03 -1.0%	$1.12	$1.03 ▼ $1.95	$64.40M	1.24	532,402 shs	220,270 shs
QTTB Q32 Bio	$15.41 -1.7%	$14.08	$1.62 ▼ $23.57	$265.71M	0.23	1.18 million shs	614,783 shs
RNAC Cartesian Therapeutics	$8.59 -1.9%	$8.66	$5.60 ▼ $12.25	$265.03M	0.63	128,229 shs	74,751 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MGNX MacroGenics	-3.92%	+0.51%	-9.47%	+13.62%	+166.67%
PLRX Pliant Therapeutics	-0.96%	-1.90%	-8.04%	-11.97%	-39.41%
QTTB Q32 Bio	-1.66%	-4.64%	+37.47%	+159.43%	+760.89%
RNAC Cartesian Therapeutics	-1.94%	+6.58%	-9.20%	+2.02%	-22.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MGNX MacroGenics	$3.92 -3.9%	$4.23	$1.29 ▼ $5.08	$259.34M	1.2	724,178 shs	477,328 shs
PLRX Pliant Therapeutics	$1.03 -1.0%	$1.12	$1.03 ▼ $1.95	$64.40M	1.24	532,402 shs	220,270 shs
QTTB Q32 Bio	$15.41 -1.7%	$14.08	$1.62 ▼ $23.57	$265.71M	0.23	1.18 million shs	614,783 shs
RNAC Cartesian Therapeutics	$8.59 -1.9%	$8.66	$5.60 ▼ $12.25	$265.03M	0.63	128,229 shs	74,751 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MGNX MacroGenics	-3.92%	+0.51%	-9.47%	+13.62%	+166.67%
PLRX Pliant Therapeutics	-0.96%	-1.90%	-8.04%	-11.97%	-39.41%
QTTB Q32 Bio	-1.66%	-4.64%	+37.47%	+159.43%	+760.89%
RNAC Cartesian Therapeutics	-1.94%	+6.58%	-9.20%	+2.02%	-22.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MGNX MacroGenics	2.29	Hold	$5.50	40.31% Upside
PLRX Pliant Therapeutics	1.75	Reduce	$3.00	191.26% Upside
QTTB Q32 Bio	2.67	Moderate Buy	$30.00	94.68% Upside
RNAC Cartesian Therapeutics	2.57	Moderate Buy	$32.60	279.51% Upside

Current Analyst Ratings Breakdown

Latest PLRX, RNAC, MGNX, and QTTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
8/5/2026	MGNX MacroGenics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/28/2026	QTTB Q32 Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $36.00
7/17/2026	PLRX Pliant Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	QTTB Q32 Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$20.00 ➝ $40.00
6/30/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/12/2026	RNAC Cartesian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/10/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00
6/9/2026	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
6/9/2026	RNAC Cartesian Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MGNX MacroGenics	$149.50M	1.67	N/A	N/A	$0.88 per share	4.45
PLRX Pliant Therapeutics	$1.58M	40.37	N/A	N/A	$2.95 per share	0.35
QTTB Q32 Bio	$53.74M	4.86	$1.49 per share	10.34	$6.25 per share	2.47
RNAC Cartesian Therapeutics	$1.48M	175.96	N/A	N/A	($4.14) per share	-2.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MGNX MacroGenics	-$74.62M	-$1.10	N/A	N/A	N/A	-44.79%	-147.80%	-28.40%	8/13/2026 (Estimated)
PLRX Pliant Therapeutics	-$149.34M	-$1.84	N/A	N/A	N/A	N/A	-58.11%	-44.37%	N/A
QTTB Q32 Bio	$29.82M	$3.00	5.14	N/A	N/A	N/A	50.17%	29.49%	N/A
RNAC Cartesian Therapeutics	-$130.30M	-$5.94	N/A	N/A	N/A	-8,550.65%	N/A	-29.84%	N/A

Latest PLRX, RNAC, MGNX, and QTTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MGNX MacroGenics	-$0.0779	N/A	N/A	N/A	$59.14 million	N/A
8/11/2026	Q2 2026	PLRX Pliant Therapeutics	-$0.3478	-$0.36	-$0.0122	-$0.36	N/A	N/A
8/6/2026	Q2 2026	RNAC Cartesian Therapeutics	-$0.8779	$0.46	+$1.3379	$0.46	$0.18 million	N/A
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A
5/13/2026	Q1 2026	MGNX MacroGenics	-$0.57	-$0.58	-$0.01	-$0.58	$15.24 million	$20.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MGNX MacroGenics	N/A	1.90	1.80
PLRX Pliant Therapeutics	N/A	16.89	16.89
QTTB Q32 Bio	N/A	20.30	20.30
RNAC Cartesian Therapeutics	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MGNX MacroGenics	96.89%
PLRX Pliant Therapeutics	97.30%
QTTB Q32 Bio	31.32%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
MGNX MacroGenics	13.60%
PLRX Pliant Therapeutics	8.74%
QTTB Q32 Bio	34.46%
RNAC Cartesian Therapeutics	37.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MGNX MacroGenics	430	63.56 million	54.92 million	Optionable
PLRX Pliant Therapeutics	90	61.92 million	56.51 million	Optionable
QTTB Q32 Bio	39	16.96 million	11.11 million	N/A
RNAC Cartesian Therapeutics	64	30.26 million	19.00 million	Optionable

PLRX, RNAC, MGNX, and QTTB Headlines

Recent News About These Companies

HC Wainwright Analysts Lower Earnings Estimates for RNAC

August 11 at 7:41 AM | marketbeat.com

Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

August 9 at 2:21 PM | theglobeandmail.com

Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results

August 8, 2026 | marketbeat.com

Cartesian Therapeutics (NASDAQ:RNAC) Raised to Hold at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Cartesian Therapeutics (NASDAQ:RNAC) Upgraded by Wall Street Zen to Hold Rating

August 8, 2026 | marketbeat.com

Cartesian Therapeutics Announces New Employment Inducement Grants

August 7, 2026 | globenewswire.com

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | markets.businessinsider.com

Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership

August 6, 2026 | quiverquant.comQ

Cartesian Therapeutics (RNAC) Projected to Release Earnings on Thursday

August 5, 2026 | americanbankingnews.com

Analysts Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Price Target at $32.60

August 4, 2026 | americanbankingnews.com

Cartesian Therapeutics (NASDAQ:RNAC) Raised to Hold at Zacks Research

July 31, 2026 | marketbeat.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Hold" by Analysts

July 30, 2026 | marketbeat.com

Cartesian Therapeutics (RNAC) Expected to Announce Earnings on Thursday

July 30, 2026 | marketbeat.com

Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 1.1% - Here's What Happened

July 28, 2026 | marketbeat.com

Cartesian Therapeutics Inc RNAC

July 12, 2026 | morningstar.comM

Cartesian Therapeutics (RNAC) Receives a Rating Update from a Top Analyst

July 2, 2026 | theglobeandmail.com

Cartesian Therapeutics Announces New Employment Inducement Grants

July 2, 2026 | globenewswire.com

New Strong Sell Stocks for July 1st

July 1, 2026 | zacks.com

Cartesian Therapeutics Shareholders Back Directors and Governance Measures

June 17, 2026 | tipranks.com

Cartesian Therapeutics Announces New Employment Inducement Grant

June 12, 2026 | globenewswire.com

Wedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 12, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, RNAC, MGNX, and QTTB Company Descriptions

MacroGenics NASDAQ:MGNX

$3.92 -0.16 (-3.92%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$4.22 +0.30 (+7.73%)

As of 08/11/2026 07:55 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Pliant Therapeutics NASDAQ:PLRX

$1.03 -0.01 (-0.96%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$1.07 +0.04 (+3.88%)

As of 08/11/2026 07:34 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Q32 Bio NASDAQ:QTTB

$15.41 -0.26 (-1.66%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$15.32 -0.09 (-0.55%)

As of 08/11/2026 07:40 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Cartesian Therapeutics NASDAQ:RNAC

$8.59 -0.17 (-1.94%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$8.59 +0.00 (+0.01%)

As of 08/11/2026 07:36 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRX, RNAC, MGNX, and QTTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRX, RNAC, MGNX, and QTTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRX, RNAC, MGNX, and QTTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, RNAC, MGNX, and QTTB Company Descriptions

MacroGenics NASDAQ:MGNX

Pliant Therapeutics NASDAQ:PLRX

Q32 Bio NASDAQ:QTTB

Cartesian Therapeutics NASDAQ:RNAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRX, RNAC, MGNX, and QTTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRX, RNAC, MGNX, and QTTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRX, RNAC, MGNX, and QTTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, RNAC, MGNX, and QTTB Company Descriptions

MacroGenics NASDAQ:MGNX

Pliant Therapeutics NASDAQ:PLRX

Q32 Bio NASDAQ:QTTB

Cartesian Therapeutics NASDAQ:RNAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools